Document is current
Any future updates will be listed below
-
Authors
Nadeem, Omar
Aranha, Michelle P. https://orcid.org/0000-0002-8230-5726
Redd, Robert https://orcid.org/0000-0002-1329-5288
Timonian, Michael https://orcid.org/0000-0002-1014-3502
Magidson, Sophie https://orcid.org/0009-0007-4225-135X
Lightbody, Elizabeth D.
Alberge, Jean-Baptiste https://orcid.org/0000-0002-4218-7294
Bertamini, Luca
Dutta, Ankit K.
El-Khoury, Habib
Bustoros, Mark https://orcid.org/0000-0002-4652-5449
Laubach, Jacob P.
Bianchi, Giada
O’Donnell, Elizabeth
Wu, Ting
Tsuji, Junko
Anderson, Kenneth C. https://orcid.org/0000-0002-6418-0886
Getz, Gad
Trippa, Lorenzo
Richardson, Paul G.
Sklavenitis-Pistofidis, Romanos
Ghobrial, Irene M. https://orcid.org/0000-0001-7361-3092
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A.
Cancer Research UK
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA263817)
- License Information
-
More Information
Article History
Received: 12 August 2024
Accepted: 6 December 2024
First Online: 3 January 2025
Competing interests
: O.N. reports research support from Takeda and Janssen; advisory board participation for Bristol Myers Squibb, Janssen, Sanofi, Takeda, and GPCR therapeutics; and honorarium from Pfizer. M.B. reports consultancy for Janssen, BMS, Takeda, Epizyme, Karyopharm, Menarini Biosystems, and Adaptive. G.B. reports consultancy for Prothena. E.O. reports advisory board participation and/or honoraria from Janssen, BMS, Sanofi, Pfizer, Exact; consulting for Takeda; and steering committee participation with Natera. K.A. reports consultancy for AstraZeneca, Janssen, and Pfizer; and board participation and stock options for Dynamic Cell Therapies, C4 Therapeutics, Next RNA, Oncopep, Starton, and Window. P.G.R. reports advisory board participation or consulting for Celgene (BMS), GSK, Karyopharm, Oncopeptides, Regeneron, Sanofi, and Takeda; and research grants from Oncopeptides and Karyopharm. R.S.P. is a co-founder, equity holder, and consultant for PreDICTA Bioscience. I.M.G.: Consulting/Advisory role: AbbVie, Adaptive, Amgen, Aptitude Health, Bristol Myers Squibb, GlaxoSmithKline, Huron Consulting, Janssen, Menarini Silicon Biosystems, Oncopeptides, Pfizer, Sanofi, Sognef, Takeda, Binding Site a part of Thermo Fischer Scientific, Window Therapeutics, and 10X Genomics; speaker fees from Vor Biopharma and Veeva Systems, Inc., and is a co-founder of PreDICTA Bioscience. I.M.G.’s spouse is the CMO and an equity holder of Disc Medicine. All other authors declare no conflicts of interest.
: One or more of the authors of this paper self-identifies as an underrepresented ethnic and/or gender minority in science. One or more of the authors of this paper self-identifies as a member of the LGBTQIA+ community. We support inclusive, diverse, and equitable conduct of research.
